[177Lu]Lu-PSMA I&T

DRUG4 trials

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Medical University of Vienna

Conditions

CancerProstate CancerProstate Cancer Recurrent

Phase 2

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Active, not recruitingNCT05867615

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSCancer

Start: 2023-05-25End: 2028-12-31Updated: 2025-12-03

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

RecruitingNCT05893381

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSProstate Cancer

Start: 2023-06-27End: 2032-04-30Target: 70Updated: 2025-12-03

PSMA-RLT in Biochemically Recurrent PCa

RecruitingNCT06220188

Medical University of ViennaProstate Cancer Recurrent

Start: 2024-01-15End: 2027-01-31Target: 20Updated: 2024-02-13

Neoadjuvant PSMA-RLT in Oligometastatic PCa

RecruitingNCT06259123

Medical University of ViennaProstate Cancer

Start: 2024-02-01End: 2027-06-30Target: 10Updated: 2024-02-15